Adam Koppel - Net Worth and Insider Trading

Adam Koppel Net Worth

The estimated net worth of Adam Koppel is at least $2.9 Billion dollars as of 2024-04-25. Adam Koppel is the Director, 10% Owner of Cerevel Therapeutics Holdings Inc and owns about 65,683,063 shares of Cerevel Therapeutics Holdings Inc (CERE) stock worth over $2.8 Billion. Adam Koppel is the Director of Dicerna Pharmaceuticals Inc and owns about 3,080,237 shares of Dicerna Pharmaceuticals Inc (DRNA) stock worth over $118 Million. Adam Koppel is also the Director of PTC Therapeutics Inc and owns about 2,333,333 shares of PTC Therapeutics Inc (PTCT) stock worth over $59 Million. Besides these, Adam Koppel also holds Solid Biosciences Inc (SLDB) , Aptinyx Inc (APTX) , Biogen Inc (BIIB) . Details can be seen in Adam Koppel's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Adam Koppel has not made any transactions after 2023-10-16 and currently still holds the listed stock(s).

Transaction Summary of Adam Koppel

To

Adam Koppel Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Adam Koppel owns 15 companies in total, including Aptinyx Inc (APTX) , Annexon Inc (ANNX) , and Solid Biosciences Inc (SLDB) among others .

Click here to see the complete history of Adam Koppel’s form 4 insider trades.

Insider Ownership Summary of Adam Koppel

Ticker Comapny Transaction Date Type of Owner
APTX Aptinyx Inc 2020-01-14 director
ANNX Annexon Inc 2020-07-23 10 percent owner
SLDB Solid Biosciences Inc 2018-01-30 director
DRNA Dicerna Pharmaceuticals Inc 2020-12-10 director
ARQT Arcutis Biotherapeutics Inc 2020-01-30 10 percent owner
SWTX SpringWorks Therapeutics Inc 2019-09-12 10 percent owner
REPL Replimune Group Inc 2018-07-19 10 percent owner
TRVN Trevena Inc 2014-09-17 director
MRNS Marinus Pharmaceuticals Inc 2017-09-19 10 percent owner
PTCT PTC Therapeutics Inc 2017-01-03 director
BIIB Biogen Inc 2016-06-06 EVP & Strategy and Bus. Dev.
BLSA BCLS Acquisition Corp 2020-10-21 director & 10 percent owner
FHTX Foghorn Therapeutics Inc 2020-10-22 director
RPID Rapid Micro Biosystems Inc 2021-07-14 10 percent owner
CERE Cerevel Therapeutics Holdings Inc 2023-10-16 director

Adam Koppel Latest Holdings Summary

Adam Koppel currently owns a total of 6 stocks. Among these stocks, Adam Koppel owns 65,683,063 shares of Cerevel Therapeutics Holdings Inc (CERE) as of October 16, 2023, with a value of $2.8 Billion and a weighting of 93.9%. Adam Koppel owns 3,080,237 shares of Dicerna Pharmaceuticals Inc (DRNA) as of December 10, 2020, with a value of $118 Million and a weighting of 4.02%. Adam Koppel also owns 2,333,333 shares of PTC Therapeutics Inc (PTCT) as of June 25, 2013, with a value of $59 Million and a weighting of 2.01%. The other 3 stocks Solid Biosciences Inc (SLDB) , Aptinyx Inc (APTX) , Biogen Inc (BIIB) have a combined weighting of 0.07% among all his current holdings.

Latest Holdings of Adam Koppel

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CERE Cerevel Therapeutics Holdings Inc 2023-10-16 65,683,063 41.90 2,752,120,340
DRNA Dicerna Pharmaceuticals Inc 2020-12-10 3,080,237 38.22 117,726,658
PTCT PTC Therapeutics Inc 2013-06-25 2,333,333 25.21 58,823,325
SLDB Solid Biosciences Inc 2018-01-30 132,630 8.77 1,163,165
APTX Aptinyx Inc 2020-01-14 5,558,425 0.10 533,609
BIIB Biogen Inc 2016-06-06 2,402 201.99 485,180

Holding Weightings of Adam Koppel


Adam Koppel Form 4 Trading Tracker

According to the SEC Form 4 filings, Adam Koppel has made a total of 2 transactions in Cerevel Therapeutics Holdings Inc (CERE) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Cerevel Therapeutics Holdings Inc is the acquisition of 5,480,052 shares on October 16, 2023, which cost Adam Koppel around $125 Million.

According to the SEC Form 4 filings, Adam Koppel has made a total of 2 transactions in Dicerna Pharmaceuticals Inc (DRNA) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Dicerna Pharmaceuticals Inc is the sale of 1,000,000 shares on December 10, 2020, which brought Adam Koppel around $23 Million.

According to the SEC Form 4 filings, Adam Koppel has made a total of 0 transactions in PTC Therapeutics Inc (PTCT) over the past 5 years. The most-recent trade in PTC Therapeutics Inc is the acquisition of 1,250,000 shares on June 25, 2013, which cost Adam Koppel around $19 Million.

More details on Adam Koppel's insider transactions can be found in the Insider Trading History of Adam Koppel table.

Insider Trading History of Adam Koppel

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Adam Koppel Trading Performance

GuruFocus tracks the stock performance after each of Adam Koppel's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Adam Koppel is 23.18%. GuruFocus also compares Adam Koppel's trading performance to market benchmark return within the same time period. The performance of stocks bought by Adam Koppel within 3 months outperforms 4 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Adam Koppel's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Adam Koppel

Average Return

65.36%

Average return per transaction

Outperforming Transactions

80%

4 out of 5 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 20 23.18 36.48 65.36 1.92 -24.3
Relative Return to S&P 500(%) 17.33 20.92 30.64 50.71 -8.35 -33.97

Adam Koppel Ownership Network

Ownership Network List of Adam Koppel

No Data

Ownership Network Relation of Adam Koppel


Adam Koppel Owned Company Details

What does Aptinyx Inc do?

Who are the key executives at Aptinyx Inc?

Adam Koppel is the director of Aptinyx Inc. Other key executives at Aptinyx Inc include director & CEO and President Norbert G Riedel , CFO and CBO Ashish Khanna , and 10 percent owner Bain Capital Life Sciences Investors, Llc .

Aptinyx Inc (APTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aptinyx Inc (APTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aptinyx Inc (APTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aptinyx Inc (APTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aptinyx Inc Insider Transactions

No Available Data

Adam Koppel Mailing Address

Above is the net worth, insider trading, and ownership report for Adam Koppel. You might contact Adam Koppel via mailing address: C/o Brookside Capital, Llc, John Hancock Tower, 200 Clarendon St, Boston Ma 02116.

Discussions on Adam Koppel

No discussions yet.